<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01950299</url>
  </required_header>
  <id_info>
    <org_study_id>HM20000024</org_study_id>
    <secondary_id>1R34HL121402-01</secondary_id>
    <nct_id>NCT01950299</nct_id>
  </id_info>
  <brief_title>Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)</brief_title>
  <acronym>VCU-ART3</acronym>
  <official_title>Interleukin-1 Blockade With Anakinra in Patients With ST-segment Elevation Myocardial Infarction - the Virginia Commonwealth University Anakinra Remodeling Trial 3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      VCU-ART3 is a double-blind randomized clinical trial of anakinra high dose vs anakinra
      standard dose vs placebo in patients with ST-segment elevation myocardial infarction (STEMI)
      measuring the effects on the acute rise and fall of the plasma C reactive protein levels
      during the first 14 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      VCU-ART3 is a double-blind randomized clinical trial of anakinra high dose vs anakinra
      standard dose vs placebo in patients with ST-segment elevation myocardial infarction (STEMI)
      measuring the effects on the acute rise and fall of the plasma C reactive protein levels
      during the first 14 days
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2014</start_date>
  <completion_date type="Actual">December 23, 2018</completion_date>
  <primary_completion_date type="Actual">December 23, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Phase Response (CRP Levels)</measure>
    <time_frame>14 days</time_frame>
    <description>Comparison of area-under-the-curve for CRP up to day 14</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular End-systolic Volume</measure>
    <time_frame>12 months</time_frame>
    <description>Placebo corrected interval change in left ventricular end-systolic volume over 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction</measure>
    <time_frame>12 months</time_frame>
    <description>Placebo-corrected interval changes in left ventricular ejection fraction over 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Failure</measure>
    <time_frame>12 months</time_frame>
    <description>New onset of heart failure symptoms (NYHA II-IV)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Anakinra (standard dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anakinra 100 mg daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anakinra (high dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anakinra 100 mg twice daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra 100 mg</intervention_name>
    <description>Anakinra 100 mg starting immediately and then every 24 hours</description>
    <arm_group_label>Anakinra (high dose)</arm_group_label>
    <arm_group_label>Anakinra (standard dose)</arm_group_label>
    <other_name>Kineret</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra 100 mg</intervention_name>
    <description>Anakinra 100 mg starting 12 hours after first dose and then every 24 hours (so that Anakinra is given every 12 hours)</description>
    <arm_group_label>Anakinra (high dose)</arm_group_label>
    <other_name>Kineret</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 0.67 ml injections twice daily</description>
    <arm_group_label>Anakinra (standard dose)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo injections twice daily</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

        In order to be eligible for this study, patients must meet ALL the 3 Inclusion criteria and
        NONE of the Exclusion criteria.

          1. Acute STEMI defined as chest pain (or equivalent) with an onset within 12 hours and
             ECG evidence of ST segment elevation (&gt;1 mm) in 2 or more anatomically contiguous
             leads that is new or presumably new

          2. Planned or completed coronary angiogram for potential intervention

          3. Age&gt;21

        EXCLUSION CRITERIA:

          -  Inability to give informed consent

          -  Pregnancy

          -  Preexisting congestive heart failure (American Heart Association/American College of
             Cardiology class C-D, New York Heart Association III-IV)

          -  Preexisting severe left ventricular dysfunction (EF&lt;20%)

          -  Preexisting severe valvular heart disease

          -  Active infections (acute or chronic) - excluding Hepatitis C Virus (HCV)+ with
             undetectable RNA

          -  Recent (&lt;14 days) or active use of anti-inflammatory drugs (not including
             non-steroidal anti-inflammatory drugs [NSAIDs] or corticosteroids used for IV dye
             allergy only)

          -  Chronic inflammatory disease (including but not limited to rheumatoid arthritis,
             systemic lupus erythematosus)

          -  Active malignancy - excluding carcinoma in situ [any organ] and non-melanoma skin
             cancer

          -  Anticipated need for cardiac surgery

          -  Neutropenia (absolute neutrophil count&lt;1,800/mm3)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Abbate, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 4, 2013</study_first_submitted>
  <study_first_submitted_qc>September 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2013</study_first_posted>
  <results_first_submitted>December 3, 2019</results_first_submitted>
  <results_first_submitted_qc>December 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 18, 2019</results_first_posted>
  <last_update_submitted>December 3, 2019</last_update_submitted>
  <last_update_submitted_qc>December 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT01950299/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Anakinra (Standard Dose)</title>
          <description>Anakinra 100 mg daily for 14 days</description>
        </group>
        <group group_id="P2">
          <title>Anakinra (High Dose)</title>
          <description>Anakinra 100 mg twice daily for 14 days</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo for 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Anakinra (Standard Dose)</title>
          <description>Anakinra 100 mg daily for 14 days</description>
        </group>
        <group group_id="B2">
          <title>Anakinra (High Dose)</title>
          <description>Anakinra 100 mg twice daily for 14 days</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo for 14 days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="35"/>
            <count group_id="B4" value="99"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="49" upper_limit="62"/>
                    <measurement group_id="B2" value="55" lower_limit="45" upper_limit="61"/>
                    <measurement group_id="B3" value="56" lower_limit="51" upper_limit="65"/>
                    <measurement group_id="B4" value="55" lower_limit="49" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Acute Phase Response (CRP Levels)</title>
        <description>Comparison of area-under-the-curve for CRP up to day 14</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anakinra (Standard Dose)</title>
            <description>Anakinra 100 mg daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Anakinra (High Dose)</title>
            <description>Anakinra 100 mg twice daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Phase Response (CRP Levels)</title>
          <description>Comparison of area-under-the-curve for CRP up to day 14</description>
          <units>mg x day/L (milligram x day/liter)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.03" lower_limit="23.50" upper_limit="138.72"/>
                    <measurement group_id="O2" value="86.35" lower_limit="43.44" upper_limit="122.73"/>
                    <measurement group_id="O3" value="213.75" lower_limit="131.36" upper_limit="394.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular End-systolic Volume</title>
        <description>Placebo corrected interval change in left ventricular end-systolic volume over 12 months</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anakinra (Standard Dose)</title>
            <description>Anakinra 100 mg daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Anakinra (High Dose)</title>
            <description>Anakinra 100 mg twice daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular End-systolic Volume</title>
          <description>Placebo corrected interval change in left ventricular end-systolic volume over 12 months</description>
          <units>mL (milliliters)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-8" upper_limit="6"/>
                    <measurement group_id="O2" value="4" lower_limit="-14" upper_limit="11"/>
                    <measurement group_id="O3" value="-4" lower_limit="-15" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Ejection Fraction</title>
        <description>Placebo-corrected interval changes in left ventricular ejection fraction over 12 months</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anakinra (Standard Dose)</title>
            <description>Anakinra 100 mg daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Anakinra (High Dose)</title>
            <description>Anakinra 100 mg twice daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Ejection Fraction</title>
          <description>Placebo-corrected interval changes in left ventricular ejection fraction over 12 months</description>
          <units>% (Left ventricular ejection fraction)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="-2" upper_limit="7"/>
                    <measurement group_id="O2" value="5" lower_limit="-1" upper_limit="5"/>
                    <measurement group_id="O3" value="3" lower_limit="-2" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Failure</title>
        <description>New onset of heart failure symptoms (NYHA II-IV)</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Anakinra (Standard Dose)</title>
            <description>Anakinra 100 mg daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Anakinra (High Dose)</title>
            <description>Anakinra 100 mg twice daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Failure</title>
          <description>New onset of heart failure symptoms (NYHA II-IV)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Anakinra (Standard Dose)</title>
          <description>Anakinra 100 mg daily for 14 days</description>
        </group>
        <group group_id="E2">
          <title>Anakinra (High Dose)</title>
          <description>Anakinra 100 mg twice daily for 14 days</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo for 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Heart Failure Hospitalization</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Unstable Angina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Revascularization</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke/Transient Ischemic Attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Reaction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Antonio Abbate, MD, PhD</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>804-828-0513</phone>
      <email>antonio.abbate@vcuhealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

